Table 2.
Safety outcomes.
| Safety outcomes | Anagliptin | Sitagliptin |
|---|---|---|
| (n = 177) | (n = 176) | |
| Cardiovascular events, n | 6 | 5 |
| Acute coronary syndrome, n | 1 | 1 |
| Congestive heart failure, n | 2 | 3 |
| Cerebral stroke, n | 1 | 0 |
| Subdural hematoma, n | 2 | 0 |
| Peripheral arterial disease, n | 0 | 1 |
| Malignancy, n | 5 | 1 |
| Pancreatic cancer, n | 1 | 0 |
| Colorectal cancer, n | 3 | 1 |
| Lung cancer, n | 1 | 0 |
| Benign gastrointestinal symptoms, n | 4 | 4 |
| Liver dysfunction, n | 1 | 0 |
| Infectious diseases, n | 6 | 2 |
| Other adverse events*, n | 3 | 5 |
*Other adverse events included diabetic foot, knee osteoarthrosis, vertebral compression fracture, arthralgia, hyperkalemia, palpitation, edema, and skin eruption.